what is microdose glp-1 Microdosing GLP-1s: Does It Work? Risks and Benefits Microdosing GLP-1 | AgelessRx

Semaglutide 24 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial

This variability restricted the possibility of conducting a meta-analysis and emphasized the need for standardized protocols in future research

Current FDA-approved uses for semaglutide include : Type 2 diabetes management (glycemic control) Cardiovascular risk reduction in type 2 diabetes with established CVD (Ozempic) Cardiovascular risk reduction in adults with established CVD and obesity/overweight (Wegovy) Chronic weight management in obesity or overweight with comorbidities Clinicians should prescribe semaglutide according to FDA-approved indications and established clinical guidelines, including those from the American Diabetes Association (ADA) and American College of Physicians (ACP)

If kidney function declines, dose reduction or discontinuation may be necessary

[DOI] [PubMed] [Google Scholar] 93.Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG, et al

Previously, for those with diabetes, hypertension and a low risk of atherosclerotic CV disease (10-year risk less than 15%), a blood pressure target of less than 140/90 mmHg was the recommendation